Prevalence of metabolic obesity in patients with Barrett's Oesophagus and its potential role in carcinogenesis

Prevalence of metabolic obesity in patients with Barrett's Oesophagus and its potential role in carcinogenesis: a single centre non-randomised controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN99001055

Enrollment

460

Registered

2012-01-05

Start date

2011-05-01

Completion date

Unknown

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Barrett's Oesophagus and metabolic obesity Digestive System Barrett's Oesophagus

Interventions

The study will be divided in 2 phases (total duration 12 months): Phase 1: Recruitment, collection of data, endoscopy (OGD) biopsy and histology, blood tests (duration 8 months). 1. Subjects with kn

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Able to understand the nature and requirements of the study and to provide written informed consent 2. Aged 18 - 79 years 3. Booked to undergo routine oesophagogastroduodenoscopy

Exclusion criteria

Exclusion criteria: 1. Weight loss of more than 10% in the last year 2. Known decompensated liver disease 3. Coeliac disease 4. Inflammatory bowel disease 5. Previous upper gastrointestinal tract surgery 6. Known malignancy or undergoing treatment for previously resected malignancy 7. Inability to provide informed consent

Design outcomes

Primary

Measure	Time frame
Prevalence of overweight, obesity, and metabolic obesity in subjects with Barrett's Oesophagus as compared to subjects without Barrett's Oesophagus (standardised for age and sex). All the measures will be done only once at baseline, when patients attend their endoscopy test as part of their clinical management. No follow-up is required.	—

Secondary

Measure	Time frame
1. The characteristics of body composition, metabolic parameters and serum level of adiponectin/leptin in obese, overweight and metabolic obese subjects compared to those of normal weight. 2. The prevalence of abdominal obesity (in obese and overweight subjects) and metabolic obesity in subjects with dysplastic Barrett's oesophagus compared to those without dysplasia. All the measures will be done only once at baseline, when patients attend their endoscopy test as part of their clinical management. No follow-up is required.	—

Measure

Time frame

1. The characteristics of body composition, metabolic parameters and serum level of adiponectin/leptin in obese, overweight and metabolic obese subjects compared to those of normal weight. 2. The prevalence of abdominal obesity (in obese and overweight subjects) and metabolic obesity in subjects with dysplastic Barrett's oesophagus compared to those without dysplasia. All the measures will be done only once at baseline, when patients attend their endoscopy test as part of their clinical management. No follow-up is required.

—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026